5 June 2026
In plain English
The American Diabetes Association's annual conference opens today in New Orleans. Over the next three days, Eli Lilly will show that its pill Foundayo outperformed Novo Nordisk's rival pill in a year-long study, and present full data from retatrutide — a triple-action injection where patients lost 30% of their body weight, rivaling surgery. Novo Nordisk will debut results from CagriSema, a combination injection expected to seek U.S. approval this fall. Boehringer Ingelheim enters the race too: its injection survodutide showed nearly 17% weight loss.
No forecasts moved today — the data presentations run Saturday through Monday. But by Monday night the branded weight-loss drug pipeline will be the deepest it has ever been. That matters: the more prescription options exist, the harder it gets for experimental drugs called peptides (short protein fragments used for recovery and longevity) to carve out revenue share.
All seven forecasts held.
Signal detail
48 days to PCAC. Zero vacancy appointments in 25+ weeks. Roster unchanged: 3 voting members (Fensky, Rebello, Serumaga) + 1 industry liaison, no chair, of 12 authorized. FACA ruling constrains unqualified batch-fill. Oral presentation deadline June 30 in 25 days — the next signal-rich window as industry coalition letters and safety data submissions arrive. ADA absorbs pharma media oxygen this week, reducing political pressure on PCAC appointments.
48 days to PCAC. Same vacancy dynamics. Skeptic notes that a 3-member committee reviewing 7 peptides over 2 days favors binary outcomes — all-pass or all-defer — rather than the moderate 2-of-4 scenario this forecast targets. The binary-outcome frame is becoming a structural concern for this specific basket forecast.
No launch announcement 25 days post-Q1 earnings. Month 16 post-facility-acquisition within 18–24 month M&A-to-launch base rate. [WaPo factory tour](https://www.washingtonpost.com/health/2026/05/24/weight-loss-compounder-hims-hers-is-shifting-wellness-longevity/) May 24 remains the last material signal — Tier 1 media factory access typically precedes launch by 3–6 months, centering timing at Aug–Nov. ADA week absorbs health-media bandwidth.
No new adverse events. No new top-5 outlet features. ADA week absorbs health media oxygen, narrowing the window for peptide safety features. Post-ADA / pre-PCAC late June is the next plausible media window. 299 days to resolution.
T-26 to July 1 launch. Prior auth fax form still promised "in June 2026" but not released. CMS "Spring 2026" operational guidance deadline ends June 20. BIN 028918 / PCN MEDDGLP1BR confirmed — pharmacies can configure claims systems, but cannot process claims without the prior auth form. ADA [ACHIEVE-3](https://www.prnewswire.com/news-releases/lilly-to-present-new-data-on-foundayo-mounjaro-and-retatrutide-at-the-american-diabetes-associations-86th-scientific-sessions-building-toward-a-new-era-of-choice-in-diabetes-and-obesity-care-302783855.html) data Monday is a demand-side catalyst landing in a supply-side-constrained channel. Next reassessment T-15 (June 16): if neither prior auth form nor claims guidance delivered, upgrade to 0.78 per pre-commitment.
No peptide DTC affiliate programs exist. ADA data this week deepens the branded GLP-1 pipeline to historically unprecedented depth — at least 7 distinct molecules with Phase 3 data by Monday (semaglutide, tirzepatide, orforglipron, retatrutide, CagriSema, survodutide, zenagamtide). This structural depth reinforces GLP-1 CPA dominance ($260 vs peptide $8–40). First-party: GSC impressions +14% WoW, position 16.6 (improved from 22.0) — SEO recovery continuing.
compound-peptide-property-live: holds 0.85, FLAGGED — DAY 20. Functionally resolved TRUE per operator clarification 2026-05-15. Hard deadline June 7 — 2 days. Twentieth consecutive flag. Removing from daily council deliberation on June 7 per proposed dormant-queue rule.
How Barque got smarter today
- Pipeline depth as a structural variable. Seven distinct weight-loss molecules with Phase 3 data is a new reference class. Previous eras had 1–2 options (Alli, Contrave). Heuristic: when pipeline depth exceeds 5 branded options, the "access gap" thesis for compounded alternatives weakens nonlinearly.
- Binary outcome framing. The Skeptic's observation that a 3-member PCAC reviewing 7 peptides favors all-or-nothing over moderate basket outcomes deserves formal weight. The pcac-july-multi-peptide forecast assumed full-quorum nuanced deliberation. A 3-member panel changes the expected distribution. Flag for Sunday Premortem rotation.
- T-minus protocol working. The T-30 pre-commitment trigger moved medicare-glp1-bridge-uptake from 0.72 to 0.75 on June 1 as committed. T-15 trigger (June 16) is the next checkpoint. Pre-commitments reduce anchoring bias by forcing the update when operational silence confirms the thesis.
- Sources sampled. Tier 1: FDA (PCAC roster, calendar), CMS (Bridge pages), Lilly IR, Novo Nordisk IR, HCPLive, AJMC, Medscape, BioSpace, Pharmacy Times. Tier 2 (rotated): Chain Drug Review (ADA preview), BSCG (peptide safety), Peptide Journal. Tier 3: none.